Combined treatment with denbinobin and fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma Bxpc-3 Cells

British Journal of Pharmacology

Volumn 157, Issue 7, 2009, Pages 1175-1185

  Yang, C R ^a   Guh, J H ^a   Teng, C M ^a   Chen, C C ^b   Chen, P H ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Apoptosis; Decoy receptor 3; Denbinobin; Fas ligand; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DECOY RECEPTOR 3; DENBINOBIN; FAS LIGAND; PROTEIN BAX; PROTEIN BCL XL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FAS LIGAND PROTEIN; HUMANS; PANCREATIC NEOPLASMS; PHENANTHRENES; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B;

EID: 70350303589     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00237.x     Document Type: Article

References (46)

1. Adams JM, Cory S (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326
2. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V et al. (2000). Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A 97: 1230-1235
3. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I et al. (1999). Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125: 73-84
4. Cande C, Cohen I, Daugas E, Ravagnan L, Larochette N, Zamzami N et al. (2002). Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 84: 215-222 (Pubitemid 34936520)
5. Chen HY, Shiao MS, Huang YL, Shen CC, Lin YL, Kuo YH et al. (1999). Antioxidant principles from Ephemerantha lonchophylla. J Nat Prod 62: 1225-1227
6. Chen TH, Pan SL, Guh JH, Chen CC, Huang YT, Pai HC et al. (2008). Denbinobin induces apoptosis by apoptosis-inducing factor releasing and DNA damage in human colorectal cancer HCT-116 cells. Naunyn Schmiedebergs Arch Pharmacol 378: 447-457
7. Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Fujimura T et al. (2001). Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 18: 311-316
8. Elsasser-Beile U, Gierschner D, Welchner T, Wetterauer U (2003). Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas. Anticancer Res 23: 433-437
9. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell 100: 57-70
10. Heinemann V, Labianca R, Hinke A, Louvet C (2007). Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18: 1652-1659
11. Huang YC, Guh JH, Teng CM (2005). Denbinobin-mediated antican-cer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity. J Biomed Sci 12: 113-121
12. Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA et al. (2002). Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther 1: 401-406
13. Inaba H, Shimada K, Zhou YW, Ido M, Buck S, Yonehara S et al. (2005). Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1. Int J Oncol 27: 573-579
14. Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D, Ronai Z (2003). FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 23: 3623-3635
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
16. Kim R, Emi M, Tanabe K, Arihiro K (2006). Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66: 5527-5536
17. Kim R, Emi M, Tanabe K (2007). Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14
18. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B et al. (2007). A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68: 809-816
19. Krammer PH, Galle PR, Moller P, Debatin KM (1998). CD95 (APO-1/ Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res 75: 251-273
20. Kuo CT, Hsu MJ, Chen BC, Chen CC, Teng CM, Pan SL et al. (2008). Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. Toxicol Lett 177: 48-58
21. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY et al. (1999). Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18: 3754-3760
22. Lee SH, Kim HS, Kim SY, Lee YS, Park WS, Kim SH et al. (2003). Increased expression of FLIP, an inhibitor of Fas-mediated apopto-sis, in stomach cancer. APMIS 111: 309-314
23. Lee YH, Park JD, Baek NI, Kim SI, Ahn BZ (1995). In vitro and in vivo antitumoral phenanthrenes from the aerial parts of Dendrobium nobile. Planta Med 61: 178-180
24. Li L, Luo X, Wang X (2001). Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412: 95-99
25. Li W, Zhang C, Chen C, Zhuang G (2007). Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol 4: 455-460
26. Lin TH, Chang SJ, Chen CC, Wang JP, Tsao LT (2001). Two phenan-thraquinones from Dendrobium moniliforme. J Nat Prod 64: 1084-1086
27. Lin WW, Karin M (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183
28. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B et al. (2002). TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492
29. Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR et al. (2005). Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28: 345-350
30. O'Reilly EM, Abou-Alfa GK (2007). Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 34: 347-353
31. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M et al. (2000). Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 160: 89-97
32. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703
33. von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Möller P (1998). Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58: 526-534
34. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P et al. (2001). Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemo-taxis. Cancer Res 61: 2759-2765
35. Russo S, Butler J, Ove R, Blackstock AW (2007). Locally advanced pancreatic cancer: a review. Semin Oncol 34: 327-334
36. Shen HW, Gao SL, Wu YL, Peng SY (2005). Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 11: 5926-5930
37. Shih CM, Wu JS, Ko WC, Wang LF, Wei YH, Liang HF et al. (2003). Mitochondria-mediated caspase-independent apoptosis induced by cadmium in normal human lung cells. J Cell Biochem 89: 335-347
38. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446
39. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M et al. (2002). The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5: 61-68
40. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S et al. (2003). Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106: 17-25
41. Walker PR, Saas P, Dietrich PY (1997). Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158: 4521-4524
42. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J et al. (2003). Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 105: 724-732
43. Xerri L, Devilard E, Hassoun J, Haddad P, Birg F (1997). Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 11: 1868-1877
44. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW (2004). Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to TNF superfamily and exhibiting angiostatic action. Cancer Res 64: 1122-1129
45. Yang KC, Uen YH, Suk FM, Liang YC, Wang YJ, Ho YS et al. (2005). Molecular mechanisms of denbinobin-induced anti-tumorigenesis effect in colon cancer cells. World J Gastroenterol 11: 3040-3045
46. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS (1999). A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274: 13733-13736